Interpace Biosciences Sees Volatile Gains Amid Broader Market Underperformance Interpace Biosciences stock surged 44.7% over the past week, yet it has lagged behind the US healthcare sector with a 21% annual decline. Despite recent gains, the company faces ongoing volatility, with average weekly price swings of 21%, significantly higher than broader market averages, reflecting ongoing investor uncertainty.12